In the group 226648-at, it is noteworthy that higher levels of HIF1AN expression were associated with better outcomes for BC (overall survival (OS): HR = 0.49, p < 0.001; recurrence-free survival (RFS): HR = 0.52, p < 0.001; distant metastasis-free survival (DMFS): HR = 0.55, p <0.001) (Figure 3). Here, HIF1AN is linked to breast cancer.